Novartis AG

Novartis AG

NVS
Novartis AGUS flagNew York Stock Exchange
121.68
USD
-0.44
(-0.36%)
6.38EPS
19.07P/E
240.33BMarket Cap
Jul 17Next Earn
Capital Structure

in mil. unless spec.
Working Capital

in mil. unless spec.
Growth Rates

in mil. unless spec.
Quarterly Revenue

in mil. unless spec.
Quarterly Earnings Per Share

in mil. unless spec.
Quarterly Dividends Per Share

in mil. unless spec.

Company Description

CEO
Vasant Narasimhan
Full Time Employees
75,883
Sector
Healthcare
Industry
Drug Manufacturers - General
Address
Lichtstrasse 35 Basel Switzerland 4056
IPO Date
Nov 7, 1996
Similar Companies
Business
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Company News

  • Why Novartis (NVS) is a Top Value Stock for the Long-Term

  • Novartis gets approval for first malaria drug for babies and children

  • Novartis receives approval for first malaria medicine for newborn babies and young infants

  • Here's Why Novartis (NVS) is a Strong Momentum Stock

  • Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study

  • Novartis drug Cosentyx fails late-stage trial for artery disease

  • Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)

  • Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)

  • Buy These 5 Low-Leverage Stocks Amid Wall Street's Tricky July Start

  • Novartis AG (NVS) Hits Fresh High: Is There Still Room to Run?

  • 7 Killer European Stocks To Buy In July

  • Final Trades: Novartis, Sixth Street, Amazon and the IYF

  • ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease

  • Novartis completes acquisition of Regulus Therapeutics

  • Novartis: A SWAN Worth Owning

  • 5 Large Drug Stocks That Are Poised to Ride on Sector Recovery

  • Buy These 5 Low-Leverage Stocks Amid Fresh Iran-Israel War

  • Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?

  • Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder

  • Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH